Trials / Terminated
TerminatedNCT05556265
A Study to Evaluate Efficacy and Safety of Deucravacitinib in Participants With Alopecia Areata
A Multi-center, Randomized, Double-blind, Placebo-controlled, Parallel Group, Phase 2 Study to Evaluate Clinical Efficacy and Safety of Deucravacitinib (BMS-986165) in Participants With Alopecia Areata
- Status
- Terminated
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 94 (actual)
- Sponsor
- Bristol-Myers Squibb · Industry
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to evaluate the efficacy of deucravacitinib versus placebo at Week 24 and safety and tolerability of deucravacitinib versus placebo in adults with alopecia areata.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Deucravacitinib | Specified dose on specified days |
| OTHER | Placebo | Placebo was administered. |
Timeline
- Start date
- 2022-11-08
- Primary completion
- 2024-01-06
- Completion
- 2024-05-16
- First posted
- 2022-09-27
- Last updated
- 2025-05-31
- Results posted
- 2025-02-28
Locations
28 sites across 6 countries: United States, Australia, Canada, France, Japan, Poland
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT05556265. Inclusion in this directory is not an endorsement.